ACM
ANTX icon

ADAR1 Capital Management’s AN2 Therapeutics ANTX Stock Holding History

ADAR1 Capital Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$285K Buy
58,808
+44,947
+324% +$193K 0.01% 236
2026
Q1 		$47.4K Buy
+13,861
New +$28.6K ﹤0.01% 300

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

ADAR1 Capital Management's ANTX Position: Q2 2026 in Review

ADAR1 Capital Management increased its AN2 Therapeutics (ANTX) stake by 324% in Q2 2026, buying an estimated $193K and bringing the position to 58,808 shares worth $285K. The position accounts for 0.01% of the portfolio, ranked #236.

ADAR1 Capital Management first reported a position in ANTX in Q1 2026 and has held it in 2 quarters since. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • ADAR1 Capital Management held 58,808 shares of AN2 Therapeutics worth $285K as of Q2 2026.
  • ADAR1 Capital Management bought 44,947 AN2 Therapeutics shares in Q2 2026, an estimated $193K.
  • AN2 Therapeutics made up 0.01% of ADAR1 Capital Management's portfolio in Q2 2026, its #236 holding.
  • ADAR1 Capital Management first reported a position in AN2 Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.